No embecta-made syringes impacted by FDA safety communication

Rhea-AI Summary

Embecta Corp. (EMBC) issues a statement regarding the U.S. FDA Safety Communication on plastic syringes, clarifying that the notice only applies to products made in China and has no impact on their production or sale. The company emphasizes its 100-year legacy of quality and innovation, assuring customers of its commitment to healthcare.

PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes:

“embecta, the world’s largest manufacturer of plastic insulin syringes, manufactures all of our syringes distributed worldwide at our facility in Holdrege, Nebraska,” said Shaun Curtis, SVP, Global Manufacturing & Supply Chain. “The safety notice issued by the FDA on November 30, 2023, only applies to plastic syringes made in China, and therefore has no impact on the ongoing production or sale of any embecta syringe products.”

“In the coming year, embecta will mark 100 years since our predecessors developed the world’s first syringe dedicated to insulin delivery, and we are proud of our rich heritage of quality, reliability, and innovation that we have earned in the years since. Our skilled workforce in Nebraska, with its unmatched expertise in high volume syringe manufacturing, is prepared to support any healthcare customers who may be affected by the FDA’s safety communication.”

About embecta 
embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.

Contacts:

Media		Investors
Christian Glazar		Pravesh Khandelwal
Sr. Director, Corporate Communications		VP, Head of Investor Relations
908-821-6922		551-264-6547
Contact Media Relations		Contact IR

FAQ

What is the U.S. FDA Safety Communication related to Embecta Corp. (EMBC)?

The U.S. FDA issued a safety communication regarding the evaluation of certain plastic syringes, which embecta clarified only applies to products made in China and does not affect their production or sale.

Where does Embecta Corp. (EMBC) manufacture its syringes?

Embecta manufactures all of its syringes distributed worldwide at its facility in Holdrege, Nebraska.

What is the significance of the upcoming 100-year mark for Embecta Corp. (EMBC)?

Embecta will mark 100 years since its predecessors developed the world’s first syringe dedicated to insulin delivery, highlighting the company's rich heritage of quality, reliability, and innovation.

How is Embecta Corp. (EMBC) prepared to support healthcare customers affected by the FDA's safety communication?

Embecta's skilled workforce in Nebraska is ready to support any healthcare customers who may be affected by the FDA’s safety communication, emphasizing their expertise in high volume syringe manufacturing.

What is the current stock performance of Embecta Corp. (EMBC)?

As of the latest available data, Embecta Corp. (EMBC) stock performance is [insert performance data here].